Pfizer und BioNTech geben Update zu mRNA-basiertem Kombinationsimpfstoffprogramm gegen Grippe und COVID-19 bei Personen im Alter von 18 bis 64 Jahren bekannt
16 août 2024 06h45 HE
|
BioNTech SE
Pfizers und BioNTechs Kombinationsimpfstoffkandidat gegen Grippe und COVID-19 hat in einer Phase-3-Studie eines ihrer beiden primären Ziele zur Immunogenität erreichtDie Studie erreichte eines ihrer...
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
16 août 2024 06h45 HE
|
BioNTech SE
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectivesThe trial did not meet one of its primary...
BioNTech gibt erste positive Ergebnisse aus laufender Phase-2-Studie mit mRNA-basiertem Immuntherapiekandidaten BNT111 bei fortgeschrittenem Hautkrebs bekannt
30 juil. 2024 06h45 HE
|
BioNTech SE
Primärer Endpunkt in Phase-2-Studie erreicht, in der der mRNA-Immuntherapiekandidat BNT111 in Kombination mit dem PD-1-Checkpoint-Inhibitor Cemiplimab evaluiert wirdDaten zeigten eine statistisch...
BioNTech Announces Positive Topline Phase 2 Results for mRNA Immunotherapy Candidate BNT111 in Patients with Advanced Melanoma
30 juil. 2024 06h45 HE
|
BioNTech SE
Primary endpoint met in a Phase 2 trial evaluating the investigational mRNA immunotherapy BNT111 in combination with the PD-1 checkpoint inhibitor cemiplimabData demonstrated a statistically...
mRNA Platform Global Strategic Research Analysis 2023-2030: US Holds Leading Position, while Asia-Pacific Exhibits Lucrative Growth in mRNA Vaccines Market
09 juil. 2024 06h09 HE
|
Research and Markets
Dublin, July 09, 2024 (GLOBE NEWSWIRE) -- The "mRNA Platform - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for mRNA Platform was...
Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an Omikron JN.1 angepassten COVID-19-Impfstoff in der Europäischen Union
27 juin 2024 10h30 HE
|
BioNTech SE
Der aktualisierte COVID-19-Impfstoff ist auf die Omikron JN.1-Sublinie von SARS-CoV-2 zugeschnitten und wird für Personen ab 6 Monaten empfohlenDie Beurteilung basiert auf präklinischen und...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
27 juin 2024 10h30 HE
|
BioNTech SE
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and...
Global Vaccine Delivery Devices Market Analysis & Forecast 2024-2034
27 mai 2024 04h01 HE
|
Research and Markets
Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccine Delivery Devices Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global...
Global $94B+ Vaccines Market Outlook, 2024-2030 by Type, Technology, Indication, Route of Administration, Age Group and Region - Rising Need for DPT Vaccine for Protection Against Serious Respiratory Ailments
08 mai 2024 03h50 HE
|
Research and Markets
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccines Market by Type (Monovalent Vaccine, Multivalent Vaccine), Technology Type (Inactivated Vaccines, Live-Attenuated Vaccines, Messenger RNA...
Global Vaccine Adjuvants Market Size, Share & Industry Trends Analysis, 2023-2030, Featuring Profiles of GSK, Novavax, SPI Pharma (Associated British Foods), Agenus, and CSL Among Others
10 avr. 2024 04h05 HE
|
Research and Markets
Dublin, April 10, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccine Adjuvants Market Size, Share & Industry Trends Analysis, 2023-2030" report has been added to ResearchAndMarkets.com's offering.The...